Press release
Global Ovarian Cancer Drugs Market to See Rapid Growth, Driven by Technological Advancements and New Drug Developments
Ovarian Cancer Drugs Market
Download Free Exclusive Sample PDF@ https://www.emergenresearch.com/request-sample/2518
Rising Prevalence of Ovarian Cancer and Technological Breakthroughs
Ovarian cancer, characterized by abnormal cell growth in the ovaries or fallopian tubes, is often treated with platinum-based chemotherapy. This treatment works by targeting the DNA of cancerous cells, leading to their destruction. The growing prevalence of ovarian cancer has spurred innovation in drug development, with major pharmaceutical companies introducing new treatments.
In November 2022, ImmunoGen Inc. announced the FDA's approval of ELAHERE (mirvetuximab soravtansine-gynx), a new antibody-drug conjugate (ADC) designed to treat adult patients with platinum-resistant ovarian cancer. This marked a significant milestone as it became the first FDA-approved ADC for such cases.
Additionally, clinical trials are underway to explore novel therapies. For example, Anixa Biosciences, in collaboration with Moffitt Cancer Center, initiated a clinical trial in August 2022 to assess the safety and effectiveness of a novel CAR-T therapy targeting ovarian cancer.
Market Drivers
The increasing incidence of ovarian cancer is a primary driver for the growth of the ovarian cancer drugs market. According to the American Cancer Society, approximately 19,710 new cases of ovarian cancer were reported in the U.S. in 2023, with the disease remaining one of the top causes of cancer-related deaths among women.
Recent clinical trials are also contributing to market growth. A phase 2 trial led by the Royal Marsden NHS Foundation Trust in June 2023 introduced a new drug combination that showed tumor shrinkage in nearly half of the patients involved. This highlights the potential for new treatments to improve patient outcomes.
Preclinical studies are also paving the way for future advancements. In April 2023, researchers from the University of Pennsylvania identified a new target for drug-resistant ovarian cancer, providing new avenues for the development of effective therapies.
Technological Advancements
One of the key trends in the market is the development of targeted therapies, particularly for platinum-resistant ovarian cancer. These therapies specifically target cancerous cells while minimizing damage to healthy cells, offering a more effective treatment with fewer side effects.
In May 2020, AstraZeneca and MSD Inc. launched a combination therapy of Lynparza (olaparib) and bevacizumab, which significantly reduces the risk of disease progression in patients with advanced ovarian cancer. This therapy has demonstrated a 67% reduction in disease progression or death.
Challenges
While the market is poised for growth, certain challenges may hinder progress. For example, the side effects of cancer treatments can be severe, and some drugs have been recalled due to safety concerns. In November 2022, GlaxoSmithKline restricted its ovarian cancer drug, Zejula, after clinical trials revealed an increased risk of death among certain patients. Such challenges underscore the need for ongoing monitoring and regulatory oversight in drug development.
Market Segmentation
The ovarian cancer drugs market is segmented by treatment type, with targeted therapy accounting for the largest revenue share in 2022. This is largely due to the effectiveness of targeted treatments, which attack cancer cells while sparing healthy ones. Leading pharmaceutical companies continue to invest in clinical trials focused on targeted therapies.
Immunotherapy, a promising approach for treating ovarian cancer, is also gaining traction. In February 2023, researchers at the Karolinska Institute developed a new type of immunotherapy that modifies a patient's T-cells to specifically target cancer cells.
Route of Administration
In terms of drug delivery, oral administration is expected to dominate the market due to its convenience and cost-effectiveness. Many ovarian cancer drugs, including oral chemotherapeutic agents, are widely available and continue to be developed by major companies. The parenteral (injectable) route is also important, particularly for intravenous chemotherapy treatments, which offer high drug bioavailability.
In September 2023, Ipsen introduced a new intravenous chemotherapy drug, Irinotecan hydrochloride, for use in phase 2 clinical trials for ovarian cancer, further expanding treatment options.
Interested in knowing more relevant information? Click here: https://www.emergenresearch.com/industry-report/ovarian-cancer-drugs-market
Ovarian Cancer Drugs Market Top Companies and Competitive Landscape
The global ovarian cancer drugs market is fairly fragmented, with many large and medium-sized players accounting for majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, testing, and introducing more effective ovarian cancer drugs solutions.
Some major players included in the global ovarian cancer drugs market report are:
Johnson & Johnson Services, Inc.
Hoffmann-La Roche Ltd.
Pfizer Inc.
Kroll (Clovis Oncology Inc.)
AbbVie Inc.
Boehringer Ingelheim International GmbH
GSK plc
Amgen Inc.
ImmunoGen Inc.
Vivesto AB
AstraZeneca
Merck KGaA
Eli Lilly and Company
Genentech, Inc.
Janssen Global Services, LLC
Novartis AG
Sun Pharmaceutical Industries Ltd.
Bayer AG
Abbott
Aurobindo Pharma
Sanofi
Teva Pharmaceutical Industries Ltd.
Ovarian Cancer Drugs Market Latest Industry Updates
On 29 August 2023, Takeda a Japan-based biopharmaceutical company announced exclusive licensing agreement with ImmunoGen, Inc. for development and commercialization of mirvetuximab soravtansine-gynx for the Japanese market for ovarian cancer treatment. MIRV is an intravenous injection Antibody-Drug Conjugate (ADC) first ADC developed for treatment of ovarian cancer, that target on microtubule in tumor cells that link to an anti-folate receptor-α (FRα) antibody. Takeda will continue development mirvetuximab soravtansine-gynx in Japan to enable treatment of FRα-positive ovarian cancer.
On 27 July 2023, Mersana Therapeutics, Inc. a clinical-stage biopharmaceutical company of Antibody-Drug Conjugates (ADCs) announced top-line data from clinical trial for platinum-resistant ovarian cancer patients and strategic reprioritization.
Ovarian Cancer Drugs Market Segmentation Analysis
For the purpose of this report, Emergen Research has segmented the global ovarian cancer drugs market on the basis of treatment type, route of administration, cancer type, distribution channel, end-use, and region:
Treatment Type Outlook (Revenue, USD Billion; 2019-2032)
Chemotherapy
Targeted Therapy
Immunotherapy
Hormonal Therapy
Surgery and Others
Route of Administration Outlook (Revenue, USD Billion; 2019-2032)
Oral
Parenteral
Others
Cancer Type Outlook (Revenue, USD Billion; 2019-2032)
Epithelial Ovarian Cancer
Germ Cell Tumor
Ovarian Stromal Tumor
Others
Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)
Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy
Others
End-use Outlook (Revenue, USD Billion; 2019-2032)
Hospitals
Homecare
Specialty centers
Others
Make Payment [Buy your Exclusive copy] @ https://www.emergenresearch.com/select-license/2518
Regional Outlook (Revenue, USD Billion; 2019-2032)
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Benelux
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Rest of APAC
Latin America
Brazil
Rest of LATAM
Middle East & Africa
Saudi Arabia
UAE
South Africa
Turkey
Rest of Middle East & Africa
Contact Us:
14671 110 Avenue, Surrey, British Columbia, V3R2A9
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights
About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Ovarian Cancer Drugs Market to See Rapid Growth, Driven by Technological Advancements and New Drug Developments here
News-ID: 3714038 • Views: …
More Releases from Emergen Research
Global Internet of Things (IoT) in Healthcare Market to Reach USD 299.05 Billion …
The global Internet of Things (IoT) in Healthcare Market was valued at USD 299.05 billion in 2023 and is expected to grow at a CAGR of 16.5% during the forecast period. This growth is fueled by the rising use of connected healthcare devices, increasing demand for early disease detection through remote monitoring, and growing adoption of artificial intelligence (AI) tools within IoT-based healthcare systems.
The market is also benefiting from the…
Global Stem Cell Therapy Market to Reach USD 49.2 Billion by 2034, Growing at 13 …
The global Stem Cell Therapy Market, valued at USD 13.7 billion in 2024, is projected to reach USD 49.2 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.6%. Growth is being fueled by the rising burden of chronic diseases, rapid progress in cell-based studies, and increasing investments in regenerative medicine and personalized healthcare solutions.
Stem cell therapies offer the ability to repair, replace, or restore damaged tissues…
Artificial Intelligence Strengthens Cybersecurity as Threats Grow More Sophistic …
The global Artificial Intelligence in cybersecurity market size was USD 23.8 Billion in 2023 and is expected to reach a market valuation of USD 29.44 billion by the end of 2024 registering a CAGR of 23.7% during the forecast period. The adoption of Artificial Intelligence (AI) in cybersecurity is rapidly gaining traction as organizations worldwide face increasingly complex and frequent cyber threats. By combining advanced technologies such as Machine Learning…
Global Regenerative Medicine Market to Reach USD 125.6 Billion by 2034, Growing …
The global regenerative medicine market, valued at USD 34.2 billion in 2024, is set to grow to USD 125.6 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.9%. Growth is being fueled by rising approvals of advanced therapies, strong demand for personalized treatments in cancer and orthopedics, and expanding cell and gene therapy manufacturing across major markets such as North America, Europe, and Asia.
Once seen as…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
